A New Chapter for IRD Therapeutics
According to Endpoints News, eye drop maker Ocuphire Pharma and retinal gene therapy startup Opus Genetics are joining forces in an all-stock deal. For the inherited retinal disease (IRD) community, this corporate union marks a notable shift toward dedicated development in genetic eye conditions.
Merger Details and Pipeline Focus
Under the agreement, Ocuphire will acquire the privately held Opus Genetics and adopt its name. The combined enterprise will trade under the stock ticker $IRD, explicitly reflecting its primary focus on inherited retinal diseases.
Following the transaction, Ocuphire CEO George Magrath will remain in his position, while Opus CEO Ben Yerxa will step in as president. Additionally, Jean Bennett—co-founder of Spark Therapeutics and co-developer of the landmark gene therapy Luxturna—will join the combined company's board of directors.
The newly shaped company boasts a pipeline featuring seven AAV-based gene therapies alongside a late-stage eye drop. Among its lead assets is OPGx-LCA5, a Phase 1/2 gene therapy candidate targeted at Leber congenital amaurosis 5 (LCA5), an early-onset retinal degeneration condition. Recent early clinical data reported by the companies indicated that three out of three adults in the trial showed visual improvement at the six-month mark.
What This Means for Patients and Families
Consolidations within the biotech sector often reshape how clinical programs are prioritized. For patients and families tracking treatments for rare retinal conditions, the newly branded Opus Genetics intends to advance a robust portfolio centered squarely on genetic deficiencies. As the companies move forward with approximately 20 employees, the focus remains on navigating clinical pipelines for conditions that have historically had limited treatment options.
Looking Ahead
As the transition concludes, the combined entity will operate under the Opus Genetics name and the $IRD ticker. Stakeholders and community members await further updates regarding the clinical progression of OPGx-LCA5 and the broader portfolio of AAV-based gene therapies.